216 related articles for article (PubMed ID: 29518290)
21. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Kishi N; Tsutani Y; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2325-2333. PubMed ID: 31317326
[TBL] [Abstract][Full Text] [Related]
22. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
[TBL] [Abstract][Full Text] [Related]
23. NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
Tlemsani C; Pécuchet N; Gruber A; Laurendeau I; Danel C; Riquet M; Le Pimpec-Barthes F; Fabre E; Mansuet-Lupo A; Damotte D; Alifano M; Luscan A; Rousseau B; Vidaud D; Varin J; Parfait B; Bieche I; Leroy K; Laurent-Puig P; Terris B; Blons H; Vidaud M; Pasmant E
Cancer Med; 2019 Aug; 8(9):4330-4337. PubMed ID: 31199580
[TBL] [Abstract][Full Text] [Related]
24. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
25. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
Dienstmann R; Elez E; Argiles G; Matos I; Sanz-Garcia E; Ortiz C; Macarulla T; Capdevila J; Alsina M; Sauri T; Verdaguer H; Vilaro M; Ruiz-Pace F; Viaplana C; Garcia A; Landolfi S; Palmer HG; Nuciforo P; Rodon J; Vivancos A; Tabernero J
Mol Oncol; 2017 Sep; 11(9):1263-1272. PubMed ID: 28618197
[TBL] [Abstract][Full Text] [Related]
26. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
27. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
[TBL] [Abstract][Full Text] [Related]
28. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
29. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
30. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
31. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
32. Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
Zhu D; Cao D; Shen M; Lv J
BMC Cancer; 2021 Feb; 21(1):176. PubMed ID: 33602172
[TBL] [Abstract][Full Text] [Related]
33. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
34. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
[TBL] [Abstract][Full Text] [Related]
35. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
Cernomaz AT; Macovei II; Pavel I; Grigoriu C; Marinca M; Baty F; Peter S; Zonda R; Brutsche M; Grigoriu B
BMC Pulm Med; 2016 May; 16(1):88. PubMed ID: 27215400
[TBL] [Abstract][Full Text] [Related]
36. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
Preusser M; Berghoff AS; Koller R; Zielinski CC; Hainfellner JA; Liebmann-Reindl S; Popitsch N; Geier CB; Streubel B; Birner P
Eur J Cancer; 2015 Sep; 51(13):1803-11. PubMed ID: 26164066
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile.
Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X
Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208
[TBL] [Abstract][Full Text] [Related]
39. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Pelosi G; Pellegrinelli A; Fabbri A; Tamborini E; Perrone F; Settanni G; Busico A; Picciani B; Testi MA; Militti L; Maisonneuve P; Valeri B; Sonzogni A; Proto C; Garassino M; De Braud F; Pastorino U
Virchows Arch; 2016 Jun; 468(6):651-62. PubMed ID: 27056568
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing.
Lee JW; Shin JY; Seo JS
J Appl Genet; 2018 Aug; 59(3):269-277. PubMed ID: 29525983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
